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THORACIC duct drainage (TOO) has been an effective immunosuppressive 
procedure, although the precise mode of 
action has not been determined.1-S Changes in 
the lymph percentages of Band T lympho-
cytes and other immunologic alterations after 
drainage have been noted.6.7 In the present 
study we examined thoracic duct lymphocytes 
of patients on prolonged drainage for Band T 
surface markers and la-like antigens. We 
present preliminary evidence for the occur-
rence of la and complement receptor (CR) 
bearing T cells after TOO. 
MATERIALS AND METHODS 
TOO cannulation was accomplished as previously 
reported."!" Lymphocytes were isolated from TOO 
lymph according to the method of Terasaki et aI.' Briefly. 
TOO lymph was centrifuged. the cells were resuspended 
in McCoy's media. and layered over Ficol\. Lymphocytes 
were recovered from the interface. 
Sheep erythrocyte-rosetting cells (T cells) were 
prepared as previously reported.' The percentage of T 
cells in the preparations was determined by counting 100 
viable rosetted and nonroselted cells. as indicated by 
f10urescein diacetate. 'D Roselted cells were isolated by 
centrifugation over Ficoll: Rosettes in the pellet were 
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lysed with NH.CI." Greater than 90% of these cells 
rerosetted. indicating minimal contamination of nonra-
setled cells. The percentage of CR'positive cells in the 
E-rosette and non-E-rosette populations was determined 
using yeast rosetting. which detected CR by zymosan 
fixing of Cr. '2 Yeasts were boiled for 10 min. washed 3 
times. and adjusted to 1.5 x 10' yeast/ml in 0.1% NaN l • 
One milliliter of yeast suspension was incubated with 0.5 
ml of fresh human serum for I hr at J7°C and then 
washed 3 times. A 10'/ml complement-coated yeast 
suspension was incubated with an equal volume of 
lymphocytes at 2 x 10'/ml at SoC for 30 min. A yeast 
rosette was considered positive when more than 2 yeasts 
were bound per visible lymphocyte. 
Cytotoxicity tests were carried out as previously 
described.' Production and documentation of the speci-
ficity of the rabbit anli-B-cell antisera was reported 
earlier. I! 
RESULTS 
The least square line (R-O.5. B- -0.56) in 
Fig. 1 demonstrates a slight downward trend 
in the percentage of T cells of thoracic duct 
lymphocyte preparations as a function of 
drainage time. Individual patients reflect this 
same trend but also show great fluctuations in 
the percentage of T cells. These trends are in 
agreement with previously reported work.6•7 
Rosette-positive and rosette-negative cells 
were examined for the presence of CR. Figure 
2 shows two representative samples and indi-
cates that as many as 60% of the T cells also 
had complement receptors. Moreover. when 
we examined TO lymphocytes with heterolo-
gous anti-Ia serum. we found cytotoxicity that 
indicated the appearance during drainage of 
la-like antigens on TOO cells. The percent-
ages of killing indicate that some cytotoxicity 
must be due to killing of T cells. Calculating 
from the cytotoxicity score. on the 34th drain-
age day. between 38% and 100% of patient 
E's T cells had la antigen; at 27 days, patient 
K had 18%-78% la' T cells. 
These data indicate that there are large 
populations of T cells that bear CR or la-like 
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antigens in thoracic duct drainage patients. It 
is possible that these two populations overlap 
and some of the cells in TOO lymph bear 
la-like antigens, CR, and sheep erythrocyte 
receptors. 
DISCUSSION 
Several authors have reported that la' T 
cells appear after stimulation with allogeneic 
sperm, mitogens, or B cellsKf~1U Of normal 
peripheral blood T cells, 00/0-6% have been 
reported to have fa antigens.15.18.19 Normal 
peripheral lymph may contain la' T cells in 
slightly higher percentages. ~o Increased pro-
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portions of Ia + T cells have been shown in 
some leukemias,15.18 and it is important to 
note that la antigen has been found on 
precursor lines. IS Hence, it has been proposed 
that dual-marked leukemia cells originate 
from immature populations. 21 The percent-
ages of Ia + T cells reported here are relatively 
high, compared to that found in normal 
lymph fluid or peripheral blood. 
As many as 51 % of the whole lymphocytes 
in our patients had both la and CR, as 
compared to the 0% -8% of normal peripheral 
blood lymphocytes which bear both mark-
ers.22 -27 These cells, called "0" cells, were in 
higher proportions in some patients with 
Iymphoproliferative disorders. 22•2f>..29 The data 
presented here show large percentages of T 
lymphocytes that have la antigens or CR and 
possibly a subpopulation of T cells that has 
both. 
Whereas the mechanism of immunosup-
pression by TOO has been associated with the 
lymphopenia developed by the procedure, this 
effect cannot explain the continued suppres-
sion lS and the tolerance induclionJO that has 
occurred after TOO is discontinued. Based on 
the preliminary evidence reported here. we 
propose that prolonged TOO induces cell 
surface marker changes in the TOO lympho-
cyte population similar to those found in 
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leukemia and precursor cell populations. We 
suggest that prolonged thoracic duct drainage 
induces an immature state in the immune 
system as indicated by the presence of the 
la +CR + T cells. We propose that this imma-
ture state is transient. therefore. antigen must 
be presented to the patient at the appropriate 
time for tolerance to occur. Detection of 
la+CR + T cells may be important clinically to 
optimize TDD as an immunosuppressive ther-
apy. 
Mixed lymphocyte culture experiments 
and further characterization of la +CR + T 
cells are underway to confirm the results 
presented here and to elucidate the function 
of dual-marked cells in immunosuppression. 
SUMMARY 
Thoracic duct lymphocytes from patients 
receiving thoracic duct drainage as a 
pretransplant therapy were examined for cell 
surface markers. Patients followed over the 
drainage time period showed a variable but 
decreasing percentage of E-rosette-positive 
cells in the lymph fluid. A substantial 
percentage of these E-rosette-positive cells 
also had C3 receptors on their cell surface. 
Reactions of the whole lymphocytes with a 
heteroantisera to human B-Iymphocyte anti-
gens reflected the increasing proportion of B 
cells in the samples. but also indicated that a 
fraction of the T cells have la-like antigens on 
their surface. Some cells may have all 3 
surface marker characteristics. Significance 
of these cells with respect to graft survival is 
discussed. 
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